PEGylated Domain I of Beta-2-Glycoprotein I inhibits the binding coagulopathic, and thrombogenic properties of IgG From patients with the antiphospholipid syndrome

Thomas C.R. McDonnell, Rohan Willis, Charis Pericleous, Vera M. Ripoll, Ian P. Giles, David A. Isenberg, Allan R. Brasier, Emilio Gonzalez, Elizabeth Papalardo, Zurina Romay-Penabad, Mohammad Jamaluddin, Yiannis Ioannou, Anisur Rahman

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

APS is an autoimmune disease in which antiphospholipid antibodies (aPL) cause vascular thrombosis and pregnancy morbidity. In patients with APS, aPL exert pathogenic actions by binding serum beta-2-glycoprotein I (β2GPI) via its N-terminal domain I (DI). We previously showed that bacterially-expressed recombinant DI inhibits biological actions of IgG derived from serum of patients with APS (APS-IgG). DI is too small (7 kDa) to be a viable therapeutic agent. Addition of polyethylene glycol (PEGylation) to small molecules enhances the serum half-life, reduces proteolytic targeting and can decrease immunogenicity. It is a common method of tailoring pharmacokinetic parameters and has been used in the production of many therapies in the clinic. However, PEGylation of molecules may reduce their biological activity, and the size of the PEG group can alter the balance between activity and half-life extension. Here we achieve production of site-specific PEGylation of recombinant DI (PEG-DI) and describe the activities in vitro and in vivo of three variants with different size PEG groups. All variants were able to inhibit APS-IgG from: binding to whole β2GPI in ELISA, altering the clotting properties of human plasma and promoting thrombosis and tissue factor expression in mice. These findings provide an important step on the path to developing DI into a first-in-class therapeutic in APS.

Original languageEnglish (US)
Article number2413
JournalFrontiers in Immunology
Volume9
Issue numberOCT
DOIs
StatePublished - Oct 22 2018

Fingerprint

beta 2-Glycoprotein I
Antiphospholipid Syndrome
Antiphospholipid Antibodies
Immunoglobulin G
Half-Life
Thrombosis
Serum
Thromboplastin
Life Expectancy
Autoimmune Diseases
Blood Vessels
Glycoproteins
Therapeutics
Pharmacokinetics
Enzyme-Linked Immunosorbent Assay
Morbidity
Pregnancy

Keywords

  • Antiphospholipid syndrome
  • Biologics
  • Domain I
  • PEGylation
  • Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

PEGylated Domain I of Beta-2-Glycoprotein I inhibits the binding coagulopathic, and thrombogenic properties of IgG From patients with the antiphospholipid syndrome. / McDonnell, Thomas C.R.; Willis, Rohan; Pericleous, Charis; Ripoll, Vera M.; Giles, Ian P.; Isenberg, David A.; Brasier, Allan R.; Gonzalez, Emilio; Papalardo, Elizabeth; Romay-Penabad, Zurina; Jamaluddin, Mohammad; Ioannou, Yiannis; Rahman, Anisur.

In: Frontiers in Immunology, Vol. 9, No. OCT, 2413, 22.10.2018.

Research output: Contribution to journalArticle

McDonnell, TCR, Willis, R, Pericleous, C, Ripoll, VM, Giles, IP, Isenberg, DA, Brasier, AR, Gonzalez, E, Papalardo, E, Romay-Penabad, Z, Jamaluddin, M, Ioannou, Y & Rahman, A 2018, 'PEGylated Domain I of Beta-2-Glycoprotein I inhibits the binding coagulopathic, and thrombogenic properties of IgG From patients with the antiphospholipid syndrome', Frontiers in Immunology, vol. 9, no. OCT, 2413. https://doi.org/10.3389/fimmu.2018.02413
McDonnell, Thomas C.R. ; Willis, Rohan ; Pericleous, Charis ; Ripoll, Vera M. ; Giles, Ian P. ; Isenberg, David A. ; Brasier, Allan R. ; Gonzalez, Emilio ; Papalardo, Elizabeth ; Romay-Penabad, Zurina ; Jamaluddin, Mohammad ; Ioannou, Yiannis ; Rahman, Anisur. / PEGylated Domain I of Beta-2-Glycoprotein I inhibits the binding coagulopathic, and thrombogenic properties of IgG From patients with the antiphospholipid syndrome. In: Frontiers in Immunology. 2018 ; Vol. 9, No. OCT.
@article{ac0ba5bfed4c49c8b69117a96b46d6aa,
title = "PEGylated Domain I of Beta-2-Glycoprotein I inhibits the binding coagulopathic, and thrombogenic properties of IgG From patients with the antiphospholipid syndrome",
abstract = "APS is an autoimmune disease in which antiphospholipid antibodies (aPL) cause vascular thrombosis and pregnancy morbidity. In patients with APS, aPL exert pathogenic actions by binding serum beta-2-glycoprotein I (β2GPI) via its N-terminal domain I (DI). We previously showed that bacterially-expressed recombinant DI inhibits biological actions of IgG derived from serum of patients with APS (APS-IgG). DI is too small (7 kDa) to be a viable therapeutic agent. Addition of polyethylene glycol (PEGylation) to small molecules enhances the serum half-life, reduces proteolytic targeting and can decrease immunogenicity. It is a common method of tailoring pharmacokinetic parameters and has been used in the production of many therapies in the clinic. However, PEGylation of molecules may reduce their biological activity, and the size of the PEG group can alter the balance between activity and half-life extension. Here we achieve production of site-specific PEGylation of recombinant DI (PEG-DI) and describe the activities in vitro and in vivo of three variants with different size PEG groups. All variants were able to inhibit APS-IgG from: binding to whole β2GPI in ELISA, altering the clotting properties of human plasma and promoting thrombosis and tissue factor expression in mice. These findings provide an important step on the path to developing DI into a first-in-class therapeutic in APS.",
keywords = "Antiphospholipid syndrome, Biologics, Domain I, PEGylation, Therapeutics",
author = "McDonnell, {Thomas C.R.} and Rohan Willis and Charis Pericleous and Ripoll, {Vera M.} and Giles, {Ian P.} and Isenberg, {David A.} and Brasier, {Allan R.} and Emilio Gonzalez and Elizabeth Papalardo and Zurina Romay-Penabad and Mohammad Jamaluddin and Yiannis Ioannou and Anisur Rahman",
year = "2018",
month = "10",
day = "22",
doi = "10.3389/fimmu.2018.02413",
language = "English (US)",
volume = "9",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "OCT",

}

TY - JOUR

T1 - PEGylated Domain I of Beta-2-Glycoprotein I inhibits the binding coagulopathic, and thrombogenic properties of IgG From patients with the antiphospholipid syndrome

AU - McDonnell, Thomas C.R.

AU - Willis, Rohan

AU - Pericleous, Charis

AU - Ripoll, Vera M.

AU - Giles, Ian P.

AU - Isenberg, David A.

AU - Brasier, Allan R.

AU - Gonzalez, Emilio

AU - Papalardo, Elizabeth

AU - Romay-Penabad, Zurina

AU - Jamaluddin, Mohammad

AU - Ioannou, Yiannis

AU - Rahman, Anisur

PY - 2018/10/22

Y1 - 2018/10/22

N2 - APS is an autoimmune disease in which antiphospholipid antibodies (aPL) cause vascular thrombosis and pregnancy morbidity. In patients with APS, aPL exert pathogenic actions by binding serum beta-2-glycoprotein I (β2GPI) via its N-terminal domain I (DI). We previously showed that bacterially-expressed recombinant DI inhibits biological actions of IgG derived from serum of patients with APS (APS-IgG). DI is too small (7 kDa) to be a viable therapeutic agent. Addition of polyethylene glycol (PEGylation) to small molecules enhances the serum half-life, reduces proteolytic targeting and can decrease immunogenicity. It is a common method of tailoring pharmacokinetic parameters and has been used in the production of many therapies in the clinic. However, PEGylation of molecules may reduce their biological activity, and the size of the PEG group can alter the balance between activity and half-life extension. Here we achieve production of site-specific PEGylation of recombinant DI (PEG-DI) and describe the activities in vitro and in vivo of three variants with different size PEG groups. All variants were able to inhibit APS-IgG from: binding to whole β2GPI in ELISA, altering the clotting properties of human plasma and promoting thrombosis and tissue factor expression in mice. These findings provide an important step on the path to developing DI into a first-in-class therapeutic in APS.

AB - APS is an autoimmune disease in which antiphospholipid antibodies (aPL) cause vascular thrombosis and pregnancy morbidity. In patients with APS, aPL exert pathogenic actions by binding serum beta-2-glycoprotein I (β2GPI) via its N-terminal domain I (DI). We previously showed that bacterially-expressed recombinant DI inhibits biological actions of IgG derived from serum of patients with APS (APS-IgG). DI is too small (7 kDa) to be a viable therapeutic agent. Addition of polyethylene glycol (PEGylation) to small molecules enhances the serum half-life, reduces proteolytic targeting and can decrease immunogenicity. It is a common method of tailoring pharmacokinetic parameters and has been used in the production of many therapies in the clinic. However, PEGylation of molecules may reduce their biological activity, and the size of the PEG group can alter the balance between activity and half-life extension. Here we achieve production of site-specific PEGylation of recombinant DI (PEG-DI) and describe the activities in vitro and in vivo of three variants with different size PEG groups. All variants were able to inhibit APS-IgG from: binding to whole β2GPI in ELISA, altering the clotting properties of human plasma and promoting thrombosis and tissue factor expression in mice. These findings provide an important step on the path to developing DI into a first-in-class therapeutic in APS.

KW - Antiphospholipid syndrome

KW - Biologics

KW - Domain I

KW - PEGylation

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85055781491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055781491&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2018.02413

DO - 10.3389/fimmu.2018.02413

M3 - Article

VL - 9

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - OCT

M1 - 2413

ER -